{
    "id": 26639,
    "fullName": "XPO1 E571K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "XPO1 E571K lies within the HEAT repeat 5 of the Xpo1 protein (UniProt.org). E571K demonstrates similar cell proliferation and viability levels as wild-type Xpo1 in one study (PMID: 29533785), however, confers a gain of function to the Xpo1 protein as demonstrated by aberrant protein localization due to increased affinity for nuclear export signal sequences with negatively charged C-termini in culture (PMID: 27312238, PMID: 31285298), increased tumorigenesis, B-cell proliferation and transformation, splenomegaly, and lethality in mouse models, and altered immune signaling and inflammatory response as demonstrated by elevated Nf-kappaB and Nfat activity in both patient and mouse cells in culture (PMID: 31285298).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9053,
                    "pubMedId": 27312238,
                    "title": "A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312238"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 17771,
                    "pubMedId": 31285298,
                    "title": "Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285298"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7514,
        "geneSymbol": "XPO1",
        "terms": [
            "XPO1",
            "CRM-1",
            "CRM1",
            "emb",
            "exp1"
        ]
    },
    "variant": "E571K",
    "createDate": "06/01/2017",
    "updateDate": "02/06/2020",
    "referenceTranscriptCoordinates": {
        "id": 86607,
        "transcript": "NM_003400",
        "gDna": "chr2:g.61492337C>T",
        "cDna": "c.1711G>A",
        "protein": "p.E571K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11060,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XPO1 E571K did not alter the sensitivity of chronic myeloid leukemia (CML) to Selinexor (KPT-330) compared to CML cells with wild-type XPO1, in culture (PMID: 27780859).",
            "molecularProfile": {
                "id": 27906,
                "profileName": "XPO1 E571K"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8936,
                    "pubMedId": 27780859,
                    "title": "The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11059,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XPO1 E571K did not alter the sensitivity of chronic myeloid leukemia (CML) to KPT-8602 compared to CML cells with wild-type XPO1 in culture (PMID: 27780859).",
            "molecularProfile": {
                "id": 27906,
                "profileName": "XPO1 E571K"
            },
            "therapy": {
                "id": 5687,
                "therapyName": "KPT-8602",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8936,
                    "pubMedId": 27780859,
                    "title": "The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell lymphoma cell lines harboring XPO1 E571K were sensitive to treatment with Xpovio (selinexor) in culture, and in cell line xenograft models, resulting in improved survival (PMID: 31285298).",
            "molecularProfile": {
                "id": 27906,
                "profileName": "XPO1 E571K"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17771,
                    "pubMedId": 31285298,
                    "title": "Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20780,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic lymphocytic leukemia cells harboring XPO1 E571K with BCL2 overexpression were sensitive to Xpovio (selinexor) treatment in culture and when engrafted into secondary recipients in mouse models (PMID: 31285298).",
            "molecularProfile": {
                "id": 35333,
                "profileName": "BCL2 over exp XPO1 E571K"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17771,
                    "pubMedId": 31285298,
                    "title": "Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27906,
            "profileName": "XPO1 E571K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35333,
            "profileName": "BCL2 over exp XPO1 E571K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 86605,
            "transcript": "XM_011533097",
            "gDna": "chr2:g.61492337C>T",
            "cDna": "c.1711G>A",
            "protein": "p.E571K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 86606,
            "transcript": "XM_006712094",
            "gDna": "chr2:g.61492337C>T",
            "cDna": "c.1711G>A",
            "protein": "p.E571K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 86607,
            "transcript": "NM_003400",
            "gDna": "chr2:g.61492337C>T",
            "cDna": "c.1711G>A",
            "protein": "p.E571K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 86608,
            "transcript": "XM_011533098",
            "gDna": "chr2:g.61492337C>T",
            "cDna": "c.1711G>A",
            "protein": "p.E571K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}